Physician profile
Pradeep Lothe
NPI 1891733721
$1,217.56
in general payments reported to CMS, 2019-2025
19 companies · $52.08 in 2025
The $52.08 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $302 · 2022: $335 · 2023: $383 · 2024: $146 · 2025: $52.08.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $581.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $581.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $324.60 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $157.89 | 2019-2023 | |
| Lilly USA, LLC | $127.56 | 2022-2024 | Verzenio, Mounjaro |
| Glaxosmithkline, LLC. | $92.81 | 2019-2023 | Nucala, Trelegy Ellipta |
| Bayer Healthcare Pharmaceuticals INC. | $79.62 | 2022-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $64.52 | 2019-2023 | |
| Idorsia Pharmaceuticals US INC | $58.60 | 2022-2023 | Quviviq |
| Bausch Health US, LLC | $45.22 | 2022 | |
| Janssen Pharmaceuticals, INC | $44.97 | 2019 | |
| Xeris Pharmaceuticals, INC. | $43.21 | 2023 | Gvoke Hypopen |
| Dexcom, INC. | $41.69 | 2023 | Dexcom G6 Transmitter |
| Daiichi Sankyo INC. | $26.83 | 2019 | |
| Novartis Pharmaceuticals Corporation | $19.87 | 2022 | |
| Almatica Pharma LLC | $17.30 | 2024 | Loreev Xr |
| E.R. Squibb & Sons, L.L.C. | $17.27 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $17.14 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $14.51 | 2023 | Farxiga |
| Astellas Pharma US INC | $12.99 | 2019 | |
| Merck Sharp & Dohme LLC | $10.96 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pradeep Lothe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.